Cocrystal Pharma, Inc.
COCP Nasdaq
SEC CIK 1412486
Follow Cocrystal Pharma
Weekly email: filings, results
Revenue, last quarter
$105K
Net income
−$3.4M
−68.1% vs same quarter last year
EPS, diluted
−$0.20
−5.3% vs same quarter last year
Operating cash flow
−$2.3M
−68.6% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | - | −$8.8M |
| FY24 | - | −$17.5M |
| FY23 | - | −$18M |
| FY22 | - | −$38.8M |
| FY21 | - | −$14.2M |
| FY20 | $2M | −$9.6M |
| FY19 | $6.6M | −$48.2M |
| FY18 | - | −$49M |
| FY17 | - | −$613K |
| FY16 | - | −$74.9M |
| FY15 | - | −$50.1M |
| FY14 | - | −$99K |
| FY13 | - | −$3.9M |
| FY12 | - | −$8M |
| FY11 | $12.7M | −$5.5M |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | - | - |
| FY24 | - | - |
| FY23 | - | - |
| FY22 | - | - |
| FY21 | - | - |
| FY20 | −476% | −479% |
| FY19 | −737.4% | −733.8% |
| FY18 | - | - |
| FY17 | - | - |
| FY16 | - | - |
| FY15 | - | - |
| FY14 | - | - |
| FY13 | - | - |
| FY12 | - | - |
| FY11 | −30.6% | −42.9% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$8.2M |
| FY24 | −$16.5M |
| FY23 | −$14.8M |
| FY22 | −$21.5M |
| FY21 | −$12.8M |
| FY20 | −$10.1M |
| FY19 | −$1.7M |
| FY18 | −$8.3M |
| FY17 | −$6.9M |
| FY16 | −$14.7M |
| FY15 | −$10.7M |
| FY14 | −$6M |
| FY13 | −$3.7M |
| FY12 | −$1.7M |
| FY11 | −$996.4K |
- Cocrystal Pharma
- Healthcare median
Show the numbers
| Year | Cocrystal Pharma | Healthcare median |
|---|---|---|
| FY25 | - | −30.6% |
| FY24 | - | −47% |
| FY23 | - | −58% |
| FY22 | - | −80.4% |
| FY21 | - | −71.9% |
| FY20 | −479% | −62.2% |
| FY19 | −733.8% | −46.3% |
| FY18 | - | −49.6% |
| FY17 | - | −45.9% |
| FY16 | - | −36% |
| FY15 | - | −38.4% |
| FY14 | - | −35.5% |
| FY13 | - | −37.1% |
| FY12 | - | −29.1% |
| FY11 | −42.9% | −27.9% |